Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT02903381
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02902965
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králové, Nový Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 46
- Registration Number
- NCT02897830
- Locations
- 🇫🇷
University Hosptial Toulouse, Toulouse, France
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: ObinutuzumabDrug: DexamethasoneDrug: AracytineDrug: CisplatinumDrug: EtoposideDrug: MelphalanDrug: Carmustine
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 86
- Registration Number
- NCT02896582
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU d'Amiens, Amiens, France
🇫🇷CH d'Avignon, Avignon, France
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 124
- Registration Number
- NCT02891811
- Locations
- 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria
DEXRAR: DEXamethasone in Revision ARthroplasty
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Daniel Hägi-Pedersen
- Target Recruit Count
- 108
- Registration Number
- NCT02884180
- Locations
- 🇩🇰
Næstved Hospital, Næstved, Region Zealand, Denmark
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeB Acute Lymphoblastic LeukemiaCentral Nervous System LeukemiaTesticular Leukemia
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneDrug: EtoposideDrug: Doxorubicin HydrochlorideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Radiation Therapy
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT02880228
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.